Subsequent clinical studies during the 2000s showed a glucose-lowering authority of DPP4 inhibitors in humans with type 2 diabetes as monotherapy or in combination with other therapies, i.e., metformin, sulfonylureas, tiazolidinediones, or exogenous insulin. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.